Market Pulse44Neutral

Agilent Technologies, Inc.Opportunity Rank #280(A) Intrinsic Value & DCF Analysis (2026)

Sector: Healthcare

Current Price

$126.49

Last updated: Jun 23, 2026

Price vs Intrinsic Value

$126.49
Price
$82.94
Intrinsic Value
Overvalued by 34%MOS: $66.35

Fundamental Score

44/100
Bearish

Weighted across 6 signals

Narrative Score

55/100
Improving

No change vs previous

Trend Score

49/100
Neutral

As of 2026-06-22

The intrinsic value of Agilent Technologies, Inc. (A) is estimated at $82.94 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $126.49, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a 3.23% long-term growth rate and a 9.23% discount rate, reflecting expected future free cash flow and cost of capital.

The intrinsic value of Agilent Technologies, Inc. (A) is estimated at $82.94 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $126.49, the stock appears overvalued relative to its projected cash flow fundamentals. This estimate assumes a 3.23% long-term growth rate and a 9.23% discount rate, reflecting expected future free cash flow and cost of capital.

Valuation Details

$82.94
-34.43% downside
20% margin of safety: $66.35
Years: 10Growth Rate: 3.23%
Want to create your own valuation? Create a free account.

Capital Efficiency

Average Quarterly ROIC
4.48%
Cost of Capital (estimated)9%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.

Fundamental Details

44/100
BearishWeighted across 6 signals
DCF Discount
34.4% premium to price
0
FCF Yield
4.6% trailing FCF yield
65
ROIC vs WACC
ROIC 4.5% vs WACC 9.0% (0.5x)
25
Net Debt / FCF
0.9x net debt to FCF
81
Buybacks
Share count flat
50
FCF CAGR (5Y)
9.6% 5Y FCF CAGR
73
Strengths: Net Debt / FCF, FCF CAGR (5Y). Concerns: DCF Discount, ROIC vs WACC.

Narrative Details

55/100
Improving
Vs 6-Month Baseline:Average (41st pct)Weighted across 6 recent drivers
Trend: StableConfidence: 95%Updated: 1h ago
Sources: 61 (48 News · 13 Analyst)
Drivers(last 30 days)
23 news sentiment+0.3
11 regulatory scrutiny+0.3
12 legal risk-0.1
Analyst downgrades-0.1
Guidance raise+0.1
Analyst upgrades+0.0

Trend Details

49/100
NeutralAs of 2026-06-22308 daily bars used
6M Relative Strength vs SPY-18.3%
21 EMA vs 50 EMA+2.8%
Distance from 52-Week High-19.5%
Price vs 21 EMA45 · -0.7%
Price vs 50 EMA60 · +2.1%
21 EMA vs 50 EMA72 · +2.8%
3M RS vs SPY45 · -1.1%
6M RS vs SPY12 · -18.3%
Distance from 52W High61 · -19.5%

Investment Coach

Updating... 12d ago
AVOIDConfidence: 83%
Thesis
Agilent Technologies, Inc. is currently overvalued with its price trading approximately 37% above the estimated fair value, supported by weak fundamentals and returns trailing its cost of capital. Despite a strong narrative score, the deteriorating trend and negative ROIC versus WACC spread suggest caution.
Key Risk
The primary risk is the continued underperformance in returns relative to the cost of capital, which could further depress valuation and investor sentiment.
Signals To Watch
  • Price moving to at least a mid-teens discount to fair value
  • Sustained improvement in ROIC versus WACC spread
  • Meaningful shifts in the narrative trend and score direction
Ask the Coach - Available with
Historical Growth Rates
Free Cash Flow- - -Trend CAGR: 3.24%5 Year CAGR (Adjusted): -0.16%

Free Cash Flow (in millions)

TTM20252024202320222021202020192018201720162015201420132012201120102009200820072006
$1,648$1,966$2,129$2,070$1,603$1,674$1,040$1,177$1,264$1,065$932$589$920$1,347$1,421$1,448$831$536$910$1,123$819

How Intrinziq Estimates Fair Value

Intrinziq estimates Agilent Technologies, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Agilent Technologies, Inc.Healthcare

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.